Mark Valadao Email & Phone Number

San Diego, Ca, Us

Molecular Axiom is a precision nucleic acid medicine company developing innovative target delivery therapies to redefine how cancer and other complex diseases are treated.Molecular Axiom develops proprietary bifunctional nucleic acid medicine that addresses both targeted delivery and targeted inhibition of genetic mutant targets focused on pancreatic cancer, neurodegenerative diseases and metabolism.

Epicrispr Biotechnologies (Epic Bio) is a leading epigenetic engineering company developing therapies to dynamically control gene expression and treat complex disease. Epic Bio was founded by genetic medicine pioneer Stanley Qi, Ph.D., named co-inventor on the Nobel Prize-winning CRISPR patent and whose fundamental work in epigenetic editing includes the invention of CRISPRa (activation) and CRISPRi (interference). Leveraging its transformational Gene Expression Modulation System (GEMS) platform, Epic Bio is developing ultracompact therapies to modulate gene expression in vivo using the smallest known Cas protein, CasMINI.

Hong Kong, Hong Kong, Hk

ORI Capital is a venture capital firm with offices in Hong Kong & Boston investing in innovative early-stage biotech companies in the U.S. & globally. ORI Capital’s competitive advantage is its quantimental approach combining a proprietary AI assisted big data platform with fundamental research that allows us to systematically address the biggest challenges facing healthcare investors:• Mitigating scientific & technology risks• Identifying the most promising early-stage companies• Providing the right resources to realize their potentialORI Capital invests in the areas of diagnostics, drug delivery, and therapeutics focused on disease areas with the highest mortality rates including cancer, cardiovascular, and neurodegenerative diseases. ORI Capital’s mission is to be both financially successful for its investors and socially impactful for patients worldwide.

Beijing, Beijing, Cn

Pagoda Capital is a healthcare-focused private equity firm founded in 2015 with offices in Beijing, Shanghai, Hong Kong, and New York. Pagoda Capital offers an innovative global healthcare investment platform with significant China synergies, leveraging a seasoned and experienced team, operational expertise, and strategic partnerships to help global healthcare firms tap opportunities in the China healthcare sector.Pagoda Capital focuses on investing in global innovations and advanced healthcare solutions spanning key verticals in Pharma/Biotech, MedTech, and Healthcare Services.

Beijing, Cn

GL Capital is a leading investment firm focused exclusively on healthcare, founded in 2010. The firm focuses on buyout and significant minority opportunities in the healthcare industry. Leveraging its in-depth sector knowledge, exceptional network, operational, scientific, and financial expertise, GL serves as both a strategic and financial partner to healthcare businesses. GL's total assets under management exceed $3.2 billion and the firm has invested in over 60 healthcare companies, with a footprint that spans the entire healthcare value chain.

Skymont Capital is a private equity firm based in Asia focused on investing in exclusive and proprietarily sourced institutional real estate opportunities across Asia Pacific for its investors and partners.

Boston, Ma, Us

Member of the senior leadership team responsible for representing SSGA investment strategies and solutions across asset classes to institutional investors in the Asia ex-Japan region. Subject matter expert communicating SSGA investment strategies to both internal and external groups such as prospects, existing clients, and consultants. These include government and corporate pension plans, sovereign wealth funds, central banks, endowments, insurance companies, and intermediaries.

New York, Ny, Us

Head of Asia Pacific Financial Products. Captured and understood market dynamics and consolidated these into a competitive business strategy to drive revenue growth. Designed business strategy and drove execution with regional sales teams, leveraging broad multi-functional internal resources across the firm to grow the financial products business.Directly managed relationships with key asset management and broker/dealer clients, institutional buyers of financial products, and stock exchanges.

Central, Hong Kong, Hk

Responsible for the overall management of Value Partners Group subsidiary - Sensible Asset Management including setting strategic objectives, overseeing business and product development as well as sales and marketing.

London, Gb

Responsible for promoting and developing multi-manager products and capabilities across all HSBC group channels including retail distribution, private client, private banking, and institutional segments across the Asia Pacific region.

Boston, Massachusetts, Us

Lead portfolio manager of the $7 billion Vanguard Asset Allocation Fund. Managed Global Tactical Asset Allocation strategy funds (+$5 billion) for global institutional clients and pension funds.